Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?

Autor: Walter P. Maksymowych, Robert D. Inman, Louis Bessette, Proton Rahman, Emmanouil Rampakakis, Odalis Asin-Milan, Meagan Rachich, Anne Marilise Marrache, Allen J. Lehman
Rok vydání: 2023
Zdroj: Arthritis Research & Therapy. 25
ISSN: 1478-6362
DOI: 10.1186/s13075-023-03055-1
Popis: Objectives To (i) determine whether sustained disease activity states, as measured by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS), impact function, and (ii) evaluate characteristics predicting sustained low functional impairment in a prospective axial spondyloarthritis (axSpA) cohort. Methods Biologic Treatment Registry Across Canada (BioTRAC) was a multi-center, prospective registry that collected real-world data on axSpA patients receiving infliximab or golimumab between 2006 and 2017. Generalized estimating equations (GEE) were used to test baseline characteristics, treatment, and duration (at 6 and 12 months vs. only at 6 or 12 months vs. neither) of low BASDAI ( Results Eight hundred ten patients were enrolled. 33.7%, 13.4%, and 24.7% achieved sustained low BASDAI, ASDAS-ID, and ASDAS-LDA, respectively. In univariable GEE of baseline variables, age and baseline BASDAI, BASFI, and ASDAS significantly predicted sustained low BASFI. In multivariable GEE, sustained low BASDAI (p p = 0.001), and baseline BASFI (p p = 0.040) and ASDAS-LDA (p Conclusion Sustained BASDAI
Databáze: OpenAIRE
Externí odkaz: